| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
BASIC SCIENCE |
University of Melbourne Departments of Medicine, St. Vincents Hospital, Victoria, Australia
Correspondence to Darren J. Kelly, Department of Medicine, St. Vincents Hospital, Fitzroy, Victoria, 3065, Australia. Phone: +61-3-9288-2580; Fax: +61-3-9288-2581; E-mail: dkelly{at}medstv.unimelb.edu.au
Pathologic fibrosis is a key feature of progressive renal disease that correlates closely with kidney dysfunction and in which the prosclerotic growth factor TGF-
has been consistently implicated. Tranilast (n-[3,4-dimethoxycinnamoyl] anthranilic acid), an antifibrotic agent that is used to treat hypertrophic scars and scleroderma, has also been shown to inhibit TGF-
induced extracellular matrix synthesis in a range of cell types, including those of renal origin. Therefore, the effects of tranilast on kidney fibrosis and dysfunction were examined in the subtotal nephrectomy model of progressive renal injury. Subtotal nephrectomy led to proteinuria and renal dysfunction in association with glomerulosclerosis, tubulointerstitial fibrosis, and macrophage accumulation. Despite persistent hypertension, treatment with tranilast led to a reduction in albuminuria (61.7 x/÷ 1.2 versus 20.5 x/÷ 1.3 mg/d; P < 0.01) and plasma creatinine (0.16 versus 0.08 mmol/L; P < 0.01) in subtotally nephrectomized rats. In addition, features suggestive of TGF-
activation, including glomerulosclerosis, tubulointerstitial fibrosis, tubular atrophy, and macrophage accumulation, all were significantly attenuated by tranilast in association with evidence of reduced TGF-
signaling in vivo. In the context of a recent pilot study in humans, the findings of the present report suggest that tranilast may provide a novel strategy for the treatment of progressive kidney disease characterized by fibrotic scarring.
This article has been cited by other articles:
![]() |
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF] |
||||
![]() |
D. J. Kelly, Y. Zhang, K. Connelly, A. J. Cox, J. Martin, H. Krum, and R. E. Gilbert Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2860 - H2869. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Tsunenari, T. Ohmura, R. Seidler, M. Chachin, T. Hayashi, A. Konomi, T. Matsumaru, T. Sumida, N. Hayashi, and Y. Horie Renoprotective effects of telmisartan in the 5/6 nephrectomised rats Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 93 - 100. [Abstract] [PDF] |
||||
![]() |
N. Oshitani, H. Yamagami, K. Watanabe, K. Higuchi, and T. Arakawa Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease Gut, April 1, 2007; 56(4): 599 - 600. [Full Text] [PDF] |
||||
![]() |
J. Soma, K. Sato, H. Saito, and Y. Tsuchiya Effect of tranilast in early-stage diabetic nephropathy Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2795 - 2799. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673